Manganese-based oral contrast agent for liver magnetic resonance imaging: Evaluation of the time course and dose response of liver signal intensity enhancement

Investigative Radiology

Volumn 45, Issue 9, 2010, Pages 565-571

  Rief, Matthias ^a   Huppertz, Alexander ^a   Asbach, Patrick ^a   Franiel, Tobias ^a   Schwenke, Carsten ^b   Hamm, Bernd ^a   Taupitz, Matthias ^a   Wagner, Moritz ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Scossis Statistical Consulting   (Germany)

Author keywords

contrast; liver; magnetic resonance; manganese; oral

Indexed keywords

CMC 001; CONTRAST MEDIUM; MANGANESE CHLORIDE TETRAHYDRATE; MANGANESE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREATH HOLDING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LIVER; LIVER INJURY; LIVER METASTASIS; LIVER PARENCHYMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; WILCOXON SIGNED RANKS TEST;

EID: 77955472295     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181e9e120     Document Type: Article

References (30)

1. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrastenhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14:559-578.
2. Ba-Ssalamah A, Uffmann M, Saini S, et al. Clinical value of MRI liverspecific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol. 2009;19:342-357.
3. Chabanova E, Logager V, Moller JM, et al. Imaging liver metastases with a new oral manganese-based contrast agent. Acad Radiol. 2006;13:827-832.
4. Chabanova E, Thomsen HS, Logager V, et al. Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0. 23, 0.6 and 1.5 T MRI, a part of a phase I trial. MAGMA. 2004;17:28-35.
5. Thomsen HS, Barentsz JO, Burcharth F, et al. Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. Eur Radiol. 2007;17:273-278.
6. Thomsen HS, Loegager V, Noergaard H, et al. Oral manganese for liver imaging at three different field strengths. Acad Radiol. 2004;11:630-636.
7. Thomsen HS, Svendsen O, Klastrup S. Increased manganese concentration in the liver after oral intake. Acad Radiol. 2004;11:38-44.
8. Bellin MF, Webb JA, Van Der Molen AJ, et al. Safety of MR liver specific contrast media. Eur Radiol. 2005;15:1607-1614.
9. Kristiansen J, Christensen JM, Iversen BS, et al. Toxic trace element reference levels in blood and urine: influence of gender and lifestyle factors. Sci Total Environ. 1997;204:147-160.
10. Pleban PA, Pearson KH. Determination of manganese in whole blood and serum. Clin Chem. 1979;25:1915-1918.
11. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrastenhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
12. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
13. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acidenhanced MR images with intraoperative findings. Radiology. 2004;230:266-275
14. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology. 2005;234:468-478.
15. Kim SH, Lee J, Kim MJ, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol. 2009;192:1675-1681.
16. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPAenhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
17. Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOBDTPA. Magn Reson Med Sci. 2007;6:43-52.
18. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (- or-2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010;45:96-103.
19. Underwood EJ. Manganese. In: Underwood EJ, ed. Trace Elements in Human and Animal Nutrition. New York, NY: Academic Press; 1997:177-207.
20. Mena I. Manganese. In: Bronner F, Coburn JW, eds. Disorders on Mineral Metabolism. New York, NY: Academic Press; 1981:233-270.
21. Keen CL, Lönnerdal B, Huerley LS. Manganese. In: Frieden J, ed. Biochemistry of the Essential Ultra-trace Elements. New York, NY: Plenum Press; 1984:89-132.
22. Korc M. Manganese homeostasis in humans and its role in disease states. In: Korc M, ed. Essential and Toxic Trace Elements in Human Health and Disease. New York, NY: Allan R. Liss; 1988:253-273.
23. Leander P, Golman K, Måsson S, et al. Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: Phase I clinical trial assessing efficacy and safety. Invest Radiol. 2010;45:559-564.
24. Marti-Bonmati L, Fog AF, de Beeck BO, et al. Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol. 2003;13:1685-1692.
25. Asbach P, Warmuth C, Stemmer A, et al. High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocytespecific contrast medium. Invest Radiol. 2008;43:809-815.
26. Schneider G, Altmeyer K, Kirchin MA, et al. Evaluation of a novel timeefficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol. 2007;42:105-115.
27. Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am. 1998;36:287-297.
28. Toft KG, Hustvedt SO, Grant D, et al. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol. 1997;38:677-689.
29. Misselwitz B, Muhler A, Weinmann HJ. A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Invest Radiol. 1995;30:611-620.
30. Thompson TN, Klaassen CD. Presystemic elimination of manganese in rats. Toxicol Appl Pharmacol. 1982;64:236-243.